Celyad Oncology S.A.

CYADNASDAQHealthcare

$0.47

$-0.07(-12.96%)

Market Cap$14238462

P/E Ratio—

52W High$3.07

52W Low$0.15

Avg Volume19K

Open$0.52

Beta1.69

Overview

Celyad Oncology S.A. (CYAD) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

cyad · stock forecast · 5 analysts (3M) · FMP · updated Aug 27, 2025

Analyst Rating & Consensus

Based on 5 Wall Street analysts in the past 3 months

Buy

5 analysts

consensus

Rating Breakdown

Strong Buy

Buy

Hold

Sell

Strong Sell

Total: 5 · Buy rate: 60.0%

12-Month Price Target

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $0.47

The Celyad Oncology S.A. (CYAD) analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month CYAD price target is $0.00, representing +0.0% upside from the current price of $0.47.

Short-Term Price Prediction

Low Activity

Algorithmically generated · Updated daily

Date	Predicted Price	Change	Min	Max
2026-06-10	$0.45	↓ 5.00%	$0.43	$0.46

1-day model range: $0.43–$0.46. Peak: $0.46 (-5.00%).

Long-Term Stock Price Prediction

⚠️ Long-term projections are hidden until 252 trading days of history (IPO / limited listing). Short-term tab may still show model output.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)30.2

MACDBEARISH

Moving Averages · CYAD · Jun 9, 2026

Simple Moving Average (SMA)

MA 5$0.56SELL

MA 10$0.57SELL

MA 20$0.62SELL

MA 50$0.77SELL

MA 100$0.00NEUTRAL

MA 200$0.00NEUTRAL

Current $CYAD · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$0.54SELL

EMA 10$0.57SELL

EMA 20$0.63SELL

EMA 50$0.81SELL

EMA 100$0.00NEUTRAL

EMA 200$0.00NEUTRAL

Current $CYAD · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:

Date	Brokerage	Action	Rating
2022-01-11	Wells Fargo	Maintains	Overweight→Overweight
2021-08-06	HC Wainwright & Co.	Maintains	Buy→Buy
2021-05-10	HC Wainwright & Co.	Maintains	Buy→Buy
2021-03-26	JonesTrading	Downgrade ↓	Buy→Hold
2020-12-08	HC Wainwright & Co.	Maintains	Buy→Buy
2020-03-26	Wells Fargo	Maintains	Overweight→Overweight
2020-03-25	H.C. Wainwright	Maintains	Buy→Buy
2016-07-05	UBS	Downgrade ↓	Buy→Neutral
2015-08-26	UBS	Maintains	Buy→Buy

Wells Fargo2022-01-11

Maintains

Overweight→Overweight

HC Wainwright & Co.2021-08-06

Maintains

Buy→Buy

HC Wainwright & Co.2021-05-10

Maintains

Buy→Buy

JonesTrading2021-03-26

Downgrade ↓

Buy→Hold

HC Wainwright & Co.2020-12-08

Maintains

Buy→Buy

Wells Fargo2020-03-26

Maintains

Overweight→Overweight

H.C. Wainwright2020-03-25

Maintains

Buy→Buy

UBS2016-07-05

Downgrade ↓

Buy→Neutral

UBS2015-08-26

Maintains

Buy→Buy

Wall Street analysts have recently issued updated ratings on Celyad Oncology S.A. (CYAD) stock. Of the recent 9 rating actions, 0 were upgrades and 2 were downgrades. 5 analysts currently cover CYAD.

Analyst Recommendation Trends

Buy ratings2 → 1↓ 1

Hold ratings0 → 0

Sell ratings0 → 0

CYAD analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

—

Revenue Next Year

—

EPS This Year

—

EPS Next Year

—

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast CYAD EPS of $— for the current fiscal year, based on estimates from 0 analysts. The CYAD revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The CYAD stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CYAD price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.

The CYAD short-term stock prediction for tomorrow is $0.45 (-5.00%).

Celyad Oncology S.A. trades on NASDAQ under the ticker CYAD. The CYAD stock outlook for 2027 is broadly positive, supported by a Buy consensus among 60% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Earnings Revenue PE Ratio Financials Market Cap Insider Trades Dividends Price History

Frequently asked questions

CYAD forecast · 8 questions

According to 5 Wall Street analysts, the average 12-month CYAD price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.47.

CYAD price targetWhat is CYAD price targetCYAD analyst price targetCYAD 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.